Home > Healthcare > Pharmaceuticals > Finished Drug Form > Non-opioid Pain Patch Market

Non-opioid Pain Patch Market Share

Report ID: GMI11974
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Non-opioid Pain Patch Market Share

The global market is highly competitive and dynamic, driven by innovation in drug delivery technologies, regulatory shifts favoring non-opioid alternatives, and growing consumer demand for OTC and natural pain relief solutions. Established pharmaceutical giants such as Hisamitsu and Teikoku Seiyaku dominate the market, while newer players are leveraging innovation and partnerships to carve out a niche. As the market continues to grow, competition will intensify, particularly in regions such as Asia Pacific and North America where demand is rising rapidly.

Non-opioid Pain Patch Market Companies

Some of the eminent market participants operating in the non-opioid pain patch industry include:

Acorda Therapeutics
AdhexPharma
Endo Pharmaceuticals
Glaxo SmithKline
Grünenthal
Hisamitsu Pharmaceutical
IBSA Institut Biochimique
Johnson & Johnson
Mylan (Viatris)
Nichiban
Pfizer
ProSolus
Sanofi
Teikoku Seiyaku
Teva Pharmaceuticals

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global non-opioid pain patch industry was valued at USD 828.3 million in 2023 and is estimated to grow at a 6.6% CAGR from 2024 to 2032, driven by the increasing prevalence of chronic pain conditions.

The lidocaine segment generated USD 357 million in revenue in 2023 and is expected to grow significantly due to its effectiveness in providing localized pain relief without opioids.

U.S. non-opioid pain patch market recorded USD 244.3 million in 2023 and is projected to witness substantial growth, fueled by stringent regulations on opioid prescriptions and FDA guidelines promoting non-opioid alternatives.

Key players in the market include Acorda Therapeutics, AdhexPharma, Endo Pharmaceuticals, Glaxo SmithKline, Gr